Kalinski Pawel, Nakamura Yutaro, Watchmaker Payal, Giermasz Adam, Muthuswamy Ravikumar, Mailliard Robbie B
Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213-1863, USA.
Immunol Res. 2006;36(1-3):137-46. doi: 10.1385/IR:36:1:137.
The work in our laboratory addresses two interrelated areas of dendritic cell (DC) biology: (1) the role of DCs as mediators of feedback interactions between NK cells, CD8+ and CD4+ T cells; and (2) the possibility to use such feedback and the paradigms derived from anti-viral responses, to promote the induction of therapeutic immunity against cancer. We observed that CD8+ T cells and NK cells, the classical "effector" cells, also play "helper" roles, regulating ability of DCs to induce type-1 immune immunity, critical for fighting tumors and intracellular pathogens. Our work aims to delineate which pathways of NK and CD8+ T cell activation result in their helper activity, and to identify the molecular mechanisms allowing them to induce type-1 polarized DCs (DC1s) with selectively enhanced ability to promote type-1 responses and anti-cancer immunity. The results of these studies allowed us and our colleagues to design phase I/II clinical trials incorporating the paradigms of DC polarization and helper activity of effector cells in cancer immunotherapy.
我们实验室的工作涉及树突状细胞(DC)生物学的两个相互关联的领域:(1)DC作为自然杀伤细胞(NK细胞)、CD8⁺和CD4⁺T细胞之间反馈相互作用介质的作用;(2)利用这种反馈以及源自抗病毒反应的范例来促进针对癌症的治疗性免疫诱导的可能性。我们观察到,经典的“效应”细胞CD8⁺T细胞和NK细胞也发挥“辅助”作用,调节DC诱导1型免疫的能力,这对于对抗肿瘤和细胞内病原体至关重要。我们的工作旨在阐明NK细胞和CD8⁺T细胞的哪些激活途径导致它们的辅助活性,并确定使它们能够诱导具有选择性增强的促进1型反应和抗癌免疫能力的1型极化DC(DC1)的分子机制。这些研究结果使我们和我们的同事能够设计出将DC极化和效应细胞辅助活性范例纳入癌症免疫治疗的I/II期临床试验。